Data & Research

Rare Cancer Data & Research

Browse below to explore the types of data RareCan uses and the types of research we support with your data

Rare Can cer Data & Research

Types of data & analyses we use

Cancer Data & Analysis
Cancer Clinical Data

Clinical Data

Clinical data includes basic information such as the age and gender of a person with cancer as well as more details about the way in which they were diagnosed and treated and how they responded to any treatment that they were given.

Tumour Data

Data about the tumour includes a description of its appearance under the microscope obtained from the NHS lab where it was analysed. This provides a histological diagnosis. This can also provide important information about how likely a tumour is to grow and spread.

Rare Cancer Genetic Data

Genetic Data

One of the key things we will be doing is collecting data about your tumour and your normal DNA. These data are really important to enable us to support research as researchers often target specific gene mutations or specific chemical signals in tumours.

Types of data & analyses we use

Types of Cancer Research

Clinical Trials

RareCan will help researchers to find enough participants in order for a clinical trial to produce meaningful results. Most new approaches will involve the use of drugs but in some cases RareCan may be able to help in the development of a new surgical treatment.

Cancer Translational Studies

Translational Studies

Translational studies bridge the gap between basic research, using cells grown in the laboratory or animals, and clinical trials. Translational research helps to identify new drug targets and ways to diagnose and monitor cancer. For this to be possible, researchers must be able to access tumour samples obtained from patients with cancer – left over after a diagnosis has been made.


RareCan will be able to facilitate a wide range of studies in addition to clinical trials and translational research. For example, it will be possible to identify members who are willing to complete questionnaires about their quality of life or their experience of diagnosis and treatment. It will also be possible to use the RareCan database to guide policy makers on the best allocation of NHS resources.